On this page

Silver Sulfadiazine

Prescription NDA TE AB Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Silver Sulfadiazine
Generic name
Silver Sulfadiazine
Dosage form
Cream
Route
Topical
Marketing category
NDA · NDA
Labeler
A-S Medication Solutions
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
2
NDC product codes
12
Packages
31
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Silver Sulfadiazine 10 g/1000g 106351 View
Silver Sulfadiazine 10 mg/g 106351 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Cream
Route of administration
Topical
Presentations
43

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Sulfonamide Antibacterial [EPC] EPC 6 members — no class page
Sulfonamides [CS] CS All 18 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
018810
Application type
NDA · New Drug Application
Approval date
December 23, 1985
Sponsor
THEPHARMANETWORK LLC
Products on application
1
Submissions recorded
13
Products approved under application 018810.
Product Trade name Form Strength Ingredient Status TE Flags
018810-001 THERMAZENE CREAM SILVER SULFADIAZINE Prescription AB

Therapeutic equivalence

Source: Orange Book
TE code
AB
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 018810.
Type No. Action Status Date Review
Supplement 20 Manufacturing (CMC) Approved August 11, 2016 N/A
Supplement 19 Manufacturing (CMC) Approved November 27, 2012 Standard
Supplement 12 Manufacturing (CMC) Approved September 27, 2001 Standard
Supplement 11 Manufacturing (CMC) Approved August 7, 1997 Standard
Supplement 8 Labeling Approved May 10, 1990 —
Supplement 7 Manufacturing (CMC) Approved October 24, 1989 Standard
Supplement 6 Manufacturing (CMC) Approved May 30, 1989 Standard
Supplement 5 Manufacturing (CMC) Approved April 12, 1989 Standard
Supplement 4 Manufacturing (CMC) Approved January 12, 1987 Standard
Supplement 2 Manufacturing (CMC) Approved November 17, 1986 Standard
Supplement 1 Manufacturing (CMC) Approved November 17, 1986 Standard
Supplement 3 Manufacturing (CMC) Approved November 4, 1986 Standard
Original application 1 Type 5 - New Formulation or New Manufacturer Approved December 23, 1985 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260713). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260713 HUMAN PRESCRIPTION DRUG · 20260512 HUMAN PRESCRIPTION DRUG · 20260317 HUMAN PRESCRIPTION DRUG · 20260123

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Silver sulfadiazine cream, USP 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION: FOR TOPICAL USE ONLY - NOT FOR OPHTHALMIC USE: Prompt institution of appropriate regimens for care of the burned patient is of prime importance and includes the control of shock and pain. The burn wounds are then cleansed and debrided; Silver Sulfadiazine Cream is then applied under sterile conditions. The burn areas should be covered with Silver Sulfadiazine Cream at all times. The cream should be applied once to twice daily to a thickness of approximately one sixteenth of an inch. Whenever necessary, the cream should be reapplied to any areas from which it has been removed due to patient activity. Administration may be accomplished in minimal time because dressings are not required. However, if individual patient requirements make dressings necessary, they may be used. Reapply immediately after hydrotherapy. Treatment with Silver Sulfadiazine Cream should be continued until satisfactory healing has occurred or until the burn site is ready for grafting. The drug should not be withdrawn from the therapeutic regimen while there remains the possibility of infection except if a significant adverse reaction occurs.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Silver sulfadiazine cream, USP 1% is contraindicated in patients who are hypersensitive to silver sulfadiazine or any of the other ingredients in the preparation. Because sulfonamide therapy is known to increase the possibility of kernicterus, silver sulfadiazine cream, USP 1% should not be used on pregnant women approaching or at term, on premature infants, or on newborn infants during the first 2 months of life.

Warnings and Cautions

openFDA Drug Labeling

Warnings and Precautions Absorption of silver sulfadiazine varies depending upon the percent of body surface area and the extent of the tissue damage. Although few have been reported, it is possible that any adverse reaction associated with sulfonamides may occur. Some of the reactions which have been associated with sulfonamides are as follows: blood dyscrasias including agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, and hemolytic anemia; dermatologic and allergic reactions, including life-threatening cutaneous reactions [Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and exfoliative dermatitis]; gastrointestinal reactions, hepatitis and hepatocellular necrosis; CNS reactions; and toxic nephrosis. There is a potential cross-sensitivity between silver sulfadiazine and other sulfonamides. If allergic reactions attributable to treatment with silver sulfadiazine occur, continuation of therapy must be weighed against the potential hazards of the particular allergic reaction. Fungal proliferation in and below the eschar may occur. However, the incidence of clinically reported fungal superinfection is low. The use of silver sulfadiazine cream, USP 1% in some cases of glucose-6-phosphate dehydrogenase-deficient individuals may be hazardous, as hemolysis may occur. General. If hepatic and renal functions become impaired and elimination of the drug decreases accumulation may occur. Discontinuation of silver sulfadiazine cream, USP 1% should be weighed against the therapeutic benefit being achieved. In considering the use of topical proteolytic enzymes in conjunction with Silver sulfadiazine cream, USP 1% the possibility should be noted that silver may inactivate such enzymes. Laboratory Tests. In the treatment of burn wounds involving extensive areas of the body, the serum sulfa concentrations may approach adult therapeutic levels (8 to 12mg %). Therefore, in these patients it would be advisable to monitor serum sulfa concentrations. Renal function should be carefully monitored and the urine should be checked for sulfa crystals. Absorption of the propylene glycol vehicle has been reported to affect serum osmolality, which may affect the interpretation of laboratory tests. Carcinogenesis, Mutagenesis, Impairment of Fertility. Long-term dermal toxicity studies of 24 months duration in rats and 18 months in mice with concentrations of silver sulfadiazine three to ten times the concentration in silver sulfadiazine cream, USP 1% revealed no evidence of carcinogenicity.

WARNINGS Absorption of silver sulfadiazine varies depending upon the percent of body surface area and the extent of the tissue damage. Although few have been reported, it is possible that any adverse reaction associated with sulfonamides may occur. Some of the reactions which have been associated with sulfonamides are as follows: blood dyscrasias including agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, and hemolytic anemia; dermatologic and allergic reactions, including life-threatening cutaneous reactions [Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and exfoliative dermatitis]; gastrointestinal reactions, hepatitis and hepatocellular necrosis; CNS reactions; and toxic nephrosis. There is a potential cross-sensitivity between silver sulfadiazine and other sulfonamides. If allergic reactions attributable to treatment with silver sulfadiazine occur, continuation of therapy must be weighed against the potential hazards of the particular allergic reaction. Fungal proliferation in and below the eschar may occur. However, the incidence of clinically reported fungal superinfection is low. The use of silver sulfadiazine cream, USP 1% in some cases of glucose-6-phosphate dehydrogenase-deficient individuals may be hazardous, as hemolysis may occur.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS SECTION Several cases of transient leucopenia have been reported in patients receiving silver sulfadiazine therapy. Leucopenia associated with silver sulfadiazine administration is primarily characterized by decreased neutrophil count. Maximal white blood cell depression occurs within two to four days of initiation of therapy. Rebound to normal leukocyte levels follows onset within two to three days. Recovery is not influenced by continuation of silver sulfadiazine therapy. The incidence of leucopenia in various reports averages about 20%. A higher incidence has been seen in patients treated concurrently with cimetidine. Other infrequently occurring events include skin necrosis, erythema multiforme, skin discoloration, burning sensation, rashes, and interstitial nephritis. Reduction in bacterial growth after application of topical antibacterial agents has been reported to permit spontaneous healing of deep partial thickness burns by preventing conversion of the partial thickness to full thickness by sepsis. However, reduction in bacterial colonization has caused delayed separation, in some cases necessitating escharotomy in order to prevent contracture. Absorption of silver sulfadiazine varies depending upon the percent of body surface area and the extent of the tissue damage. Although few have been reported, it is possible that any adverse reaction associated with sulfonamides may occur. Some of the reactions which have been associated with sulfonamides are as follows: blood dyscrasias, agranulocytosis, aplastic anemia, thrombocytopenia, leucopenia, hemolytic anemia, dermatologic reactions, allergic reactions, Stevens-Johnson syndrome, exfoliative dermatitis, gastrointestinal reactions, hepatitis, hepatocellular necrosis, CNS reactions, and toxic nephrosis.

Description

openFDA Drug Labeling

DESCRPITION SSDTM (1% Silver Sulfadiazine Cream) and SSD AFTM (1% Silver Sulfadiazine Cream), 1% are topical antibacterial preparations which have as their active antimicrobial ingredient silver sulfadiazine. The active moiety is contained within an opaque, white, water miscible cream base. Each 1000 grams of SSD/SSD AF Cream contains 10 grams of silver sulfadiazine. Inactive Ingrediants: cetyl alcohol (SSD Cream only), isopropyl myristate, polyoxyl 40 stearate, propylene glycol, purified water, stearyl alcohol, sodium hydroxide, sorbitan monooleate, white petrolatum; with 0.3% methyl paraben, as a preservative. Silver sulfadiazine has an emprical formula of C 10 H 9 AgN 4 O 2 S, molecular weight of 357.14 and structural formula as shown: Structure for silver sulfadiazine

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Silver sulfadiazine cream, USP 1% - white to off-white cream NDC Number Size 87063-078-20 (relabeled from NDC 67877-124-20) 20g tube 87063-078-25 (relabeled from NDC 67877-124-25) 25g tube 87063-078-05 (relabeled from NDC 67877-124-05) 50g tube 87063-078-85 (relabeled from NDC 67877-124-85) 85g tube 87063-078-50 (relabeled from NDC 67877-124-50) 50g jar 87063-078-40 (relabeled from NDC 67877-124-40) 400g jar 87063-078-10 (relabeled from NDC 67877-124-10) 1000g jar Store at room temperature. 15°-30°C (59°-86°F). Relabeled by: Enovachem PHARMACEUTICALS Torrance, CA 90501

Adverse event reports

Source: openFDA FAERS
2,276
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: SILVER SULFADIAZINE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
50090-0607-0 50090-0607 A-S Medication Solutions 50 g in 1 JAR (50090-0607-0) November 28, 2014
50090-0717-0 50090-0717 A-S Medication Solutions 50 g in 1 TUBE (50090-0717-0) November 28, 2014
50090-0763-0 50090-0763 A-S Medication Solutions 25 g in 1 TUBE (50090-0763-0) November 28, 2014
50090-2152-0 50090-2152 A-S Medication Solutions 400 g in 1 JAR (50090-2152-0) October 21, 2015
80425-0221-1 80425-0221 Advanced Rx Pharmacy of Tennessee, LLC 50 g in 1 TUBE (80425-0221-1) January 12, 2023
67877-124-05 67877-124 Ascend Laboratories, LLC 50 g in 1 TUBE (67877-124-05) December 23, 1985
67877-124-10 67877-124 Ascend Laboratories, LLC 1000 g in 1 JAR (67877-124-10) December 23, 1985
67877-124-20 67877-124 Ascend Laboratories, LLC 20 g in 1 TUBE (67877-124-20) December 23, 1985
67877-124-25 67877-124 Ascend Laboratories, LLC 25 g in 1 TUBE (67877-124-25) December 23, 1985
67877-124-40 67877-124 Ascend Laboratories, LLC 400 g in 1 JAR (67877-124-40) December 23, 1985
67877-124-50 67877-124 Ascend Laboratories, LLC 50 g in 1 JAR (67877-124-50) December 23, 1985
67877-124-85 67877-124 Ascend Laboratories, LLC 85 g in 1 TUBE (67877-124-85) December 23, 1985
76420-208-25 76420-208 Asclemed USA, Inc. 25 g in 1 TUBE (76420-208-25) March 9, 2022
76420-208-50 76420-208 Asclemed USA, Inc. 50 g in 1 TUBE (76420-208-50) March 9, 2022
87063-078-05 87063-078 Asclemed USA, Inc. 50 g in 1 TUBE (87063-078-05) January 23, 2026
87063-078-10 87063-078 Asclemed USA, Inc. 1000 g in 1 JAR (87063-078-10) January 23, 2026
87063-078-20 87063-078 Asclemed USA, Inc. 20 g in 1 TUBE (87063-078-20) January 23, 2026
87063-078-25 87063-078 Asclemed USA, Inc. 25 g in 1 TUBE (87063-078-25) January 23, 2026
87063-078-40 87063-078 Asclemed USA, Inc. 400 g in 1 JAR (87063-078-40) January 23, 2026
87063-078-50 87063-078 Asclemed USA, Inc. 50 g in 1 JAR (87063-078-50) January 23, 2026
87063-078-85 87063-078 Asclemed USA, Inc. 85 g in 1 TUBE (87063-078-85) January 23, 2026
61919-237-25 61919-237 DIRECT RX 25 g in 1 TUBE (61919-237-25) January 1, 2015
59762-0131-0 59762-0131 Mylan Pharmaceuticals Inc. 1 TUBE in 1 CARTON (59762-0131-0) / 20 g in 1 TUBE February 9, 2018
59762-0131-2 59762-0131 Mylan Pharmaceuticals Inc. 1 TUBE in 1 CARTON (59762-0131-2) / 25 g in 1 TUBE February 9, 2018
59762-0131-4 59762-0131 Mylan Pharmaceuticals Inc. 400 g in 1 JAR (59762-0131-4) January 16, 2018
59762-0131-5 59762-0131 Mylan Pharmaceuticals Inc. 1 TUBE in 1 CARTON (59762-0131-5) / 50 g in 1 TUBE January 16, 2018
59762-0131-6 59762-0131 Mylan Pharmaceuticals Inc. 50 g in 1 JAR (59762-0131-6) January 16, 2018
59762-0131-8 59762-0131 Mylan Pharmaceuticals Inc. 1 TUBE in 1 CARTON (59762-0131-8) / 85 g in 1 TUBE January 16, 2018
68071-2473-5 68071-2473 NuCare Pharmaceuticals,Inc. 50 g in 1 TUBE (68071-2473-5) July 8, 2021
63187-023-25 63187-023 Proficient Rx LP 25 g in 1 TUBE (63187-023-25) November 1, 2018
63187-023-51 63187-023 Proficient Rx LP 50 g in 1 TUBE (63187-023-51) February 14, 2024
50090-0607 50090-0607 A-S Medication Solutions — December 23, 1985
50090-0717 50090-0717 A-S Medication Solutions — December 23, 1985
50090-0763 50090-0763 A-S Medication Solutions — December 23, 1985
50090-2152 50090-2152 A-S Medication Solutions — December 23, 1985
80425-0221 80425-0221 Advanced Rx Pharmacy of Tennessee, LLC — January 12, 2023
67877-124 67877-124 Ascend Laboratories, LLC — December 23, 1985
76420-208 76420-208 Asclemed USA, Inc. — May 4, 2011
87063-078 87063-078 Asclemed USA, Inc. — December 23, 1985
61919-237 61919-237 DIRECT RX — January 1, 2014
59762-0131 59762-0131 Mylan Pharmaceuticals Inc. — January 15, 2018
68071-2473 68071-2473 NuCare Pharmaceuticals,Inc. — May 4, 2011
63187-023 63187-023 Proficient Rx LP — December 23, 1985

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 11 sections on this page.